Biomarkers for Hepatocellular Carcinoma

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. The HCC diagnosis is usually achieved by biomarkers, which can also help in prognosis prediction. Furthermore, it might represent certain therapeutic interventions through some combinations of biomarkers. Here, we review on our current understanding of HCC biomarkers.

Related collections

Most cited references 82

Record: found
Abstract: found
Article: not found

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.

Masao Omata, Laurentius Lesmana, Ryosuke Tateishi … (2010)

The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on the management of hepatocellular carcinoma (HCC) in December 2008 to develop consensus recommendations. The working party consisted of expert hepatologist, hepatobiliary surgeon, radiologist, and oncologist from Asian-Pacific region, who were requested to make drafts prior to the consensus meeting held at Bali, Indonesia on 4 December 2008. The quality of existing evidence and strength of recommendations were ranked from 1 (highest) to 5 (lowest) and from A (strongest) to D (weakest), respectively, according to the Oxford system of evidence-based approach for developing the consensus statements. Participants of the consensus meeting assessed the quality of cited studies and assigned grades to the recommendation statements. Finalized recommendations were presented at the fourth APASL single topic conference on viral-related HCC at Bali, Indonesia and approved by the participants of the conference.

0 comments Cited 323 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis.

Jian Xu, Chen Wu, Xu Che … (2011)

Numerous studies have shown that aberrant microRNA (miRNA) expression is associated with the development and progression of various types of human cancer and serum miRNAs are potential biomarkers. This study examined whether some commonly deregulated miRNAs in hepatocellular carcinoma (HCC) are presented in serum of patients with HCC and can serve as diagnostic markers. Serum miRNAs (miR-21, miR-122, and miR-223) were quantified by real-time quantitative RT-PCR in 101 patients with HCC and 89 healthy controls. In addition, 48 patients with chronic type B hepatitis were also analyzed for comparison. We found that the median levels of miR-21, miR-122, and miR-223 were significantly higher in patients with HCC than those in healthy controls (P = 7.48 x 10⁻¹³, P = 6.93 x 10⁻⁹, and P = 3.90 x 10⁻¹², respectively). However, these elevated serum miRNAs were also detected in patients with chronic hepatitis (P = 2.05 x 10⁻¹², P = 4.52 x 10⁻¹⁶, and P = 1.65 x 10⁻¹¹, respectively). Moreover, serum miR-21 and miR-122 in patients with chronic hepatitis were higher than in patients with HCC (P = 3.99 x 10⁻⁴ and P = 4.97 x 10⁻⁸), although no such significant difference was found for miR-223. Receiver-operator characteristic (ROC) curve analyses suggest that these serum miRNAs may be useful markers for discriminating patients with HCC or chronic hepatitis from healthy controls, but not patients with HCC from patients with chronic hepatitis. Our results indicate that serum miR-21, miR-122 and miR-223 are elevated in patients with HCC or chronic hepatitis and these miRNAs have strong potential to serve as novel biomarkers for liver injury but not specifically for HCC. Copyright © 2010 Wiley-Liss, Inc.

0 comments Cited 214 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Biomarkers for the early diagnosis of hepatocellular carcinoma.

Nobuhiro Tsuchiya, YU SAWADA, Itaru Endo … (2015)

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer-related deaths worldwide. Although the prognosis of patients with HCC is generally poor, the 5-year survival rate is > 70% if patients are diagnosed at an early stage. However, early diagnosis of HCC is complicated by the coexistence of inflammation and cirrhosis. Thus, novel biomarkers for the early diagnosis of HCC are required. Currently, the diagnosis of HCC without pathological correlation is achieved by analyzing serum α-fetoprotein levels combined with imaging techniques. Advances in genomics and proteomics platforms and biomarker assay techniques over the last decade have resulted in the identification of numerous novel biomarkers and have improved the diagnosis of HCC. The most promising biomarkers, such as glypican-3, osteopontin, Golgi protein-73 and nucleic acids including microRNAs, are most likely to become clinically validated in the near future. These biomarkers are not only useful for early diagnosis of HCC, but also provide insight into the mechanisms driving oncogenesis. In addition, such molecular insight creates the basis for the development of potentially more effective treatment strategies. In this article, we provide an overview of the biomarkers that are currently used for the early diagnosis of HCC.

0 comments Cited 209 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Journal ID (nlm-ta): Biomark Cancer

Journal ID (iso-abbrev): Biomark Cancer

Journal ID (publisher-id): Biomarkers in Cancer

Title: Biomarkers in Cancer

Publisher: Libertas Academica

ISSN (Electronic): 1179-299X

Publication date Collection: 2017

Publication date (Electronic): 28 February 2017

Volume: 9

Pages: 1-9

Affiliations

[1 ]Department of Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.

[2 ]Center for RNA Research, State Key Laboratory of Molecular Biology, Chinese Academy of Sciences (CAS), Shanghai, China.

[3 ]Department of Anatomy, Histology & Embryology, Shanghai Medical College, Fudan University, Shanghai, China.

[4 ]Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.

Author notes

CORRESPONDING AUTHORS: Shuai Jiang, Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA. Email: luckysjiang@ 123456caltech.edu

LingFei Zhang, Department of Anatomy, Histology & Embryology, Shanghai Medical College, Fudan University, Shanghai 200032, China. Email: lingfeizhang@ 123456sibcb.ac.cn

[*]

J.L. and L.Z. contributed equally to this work.

Article

Publisher ID: 10.1177_1179299x16684640

DOI: 10.1177/1179299X16684640

PMC ID: 5345949

PubMed ID: 28469485

SO-VID: e4876f59-dbb4-422a-9e75-83c097df0316

License:

This is an open access article published under the Creative Commons CC-BY-NC 3.0 license.

Biomarkers for Hepatocellular Carcinoma

Read this article at

Abstract

Related collections

Journal of Circulating Biomarkers

Most cited references 82

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.

Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis.

Biomarkers for the early diagnosis of hepatocellular carcinoma.

Author and article information

Journal

Affiliations

Author notes

Article

History

Categories

Comments

Comment on this article

Similar content 1,073

Cited by 48

Most referenced authors 1,513